New treatment hope with $7.6m Big Freeze fund
MELBOURNE: When Neale Daniher was diagnosed with motor neurone disease almost six years ago, there was not even a promising treatment on the horizon.
“When there is no drug trial, there is no hope. But now there is hope,” the AFL great said.
Today his FightMND foundation is announcing the seven new medical research projects to be funded by $7.6 million raised from last year’s MCG Big Freeze.
Three clinical trials, including a first-in-human study, will test promising therapies in humans.
Two new drugs, one of which involves an innovative way of sneaking in promising treatments across the impenetrable blood-brain-barrier, will be supported.
There is also an ambitious plan to categorise different types of MND patients based on their genetic and molecular disease profile, to better predict who could benefit from what new drug.
FightMND research manager Bec Sheean said it was a stringent review process to assess the 30 applications received researchers around the world.
“We look for evidence that a drug is likely to work; that it’s shown promise in animals, cell models, or in a similar disease,” Dr Sheean said.
“We look at if they are a research team with the expertise to deliver what they say they’re going to, and that the treatment they’re developing will be relevant to people.
“We have to keep advancing new drugs through the clinical trial pipeline until we find one that works.”
The funding pool includes $2 million of Federal Government funding, which matched dollar-for-dollar what was raised by the Australian public.
One of the key projects, the Precision Medicine Program led by Associate Professor Brad Turner at the Florey Institute of Neuroscience and Mental Health, will differentiate patients into disease subtypes.
The skin biopsies of 151 Australian MND patients — of which Daniher was the first to donate — have been turned into stem cells. Next they will become spinal motor neurons.
Using the $1 million custom-built robot the Florey received last year from FightMND, these human motor neuron cells will be tested with thousands of FDA approved drugs — everything from cold sore cream and aspirin, to antidepressants and blood pressure medication — to see if any medication already on the market can protect or repair human motor neuron cells.
And now, with their $2 million in new funding, Dr Turner and his team will drill down into the biological make-up of each individual’s disease to develop a “disease signature”.
“I think the reason MND clinical trials have failed in the last 25 years is we group all patients together, so you can’t detect the benefit,” Dr Turner said.
“But once we get a disease signature we can start to address the treatment according to that profile, so every patient benefits, just like in cancer That’s the key difference.”
But Daniher said the job was not done, and urged the public to continue supporting the cause.
“Don’t give up on us now,” he said. “MND is a beast. It’s a riddle and it will take some time to solve, but I’m hopeful we’ll find a treatment within five years.”






